ADAR1 Capital Management »

Mineralys Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Mineralys Therapeutics (MLYS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Mineralys Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Mineralys Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Mineralys Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $310k 24k 12.91

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Mineralys Therapeutics

Catalys Pacific
Samsara BioCapital
RA Capital Management
TCG Crossover Management
BlackRock
BlackRock
Sr One Capital Management
OrbiMed Advisors
Franklin Resources
Laurion Capital Management
Vanguard Group
Caligan Partners
American Century Companies
Jennison Associates
Nantahala Capital Management

View all funds holding Mineralys Therapeutics